FDA approves first biosimilar for treatment of adult patients with non-Hodgkin ’ s lymphoma

The FDA approved Truxima (rituximab-abbs) as the first biosimilar to Rituxan (rituximab) for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin ’ s lymphoma (NHL) to be used as a single agent or in combination with chemotherapy.
Source: Food and Drug Administration - Category: American Health Source Type: news